DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies ...

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as ...

Gene editing strategies, from epigenetic engineering to cell reprogramming and genetic vaccines, are accelerating the development of new therapies that awaken the immune system to treat cancer, as ...

Cancer continues to be one of the most challenging diseases due to the complex molecular mechanisms involved. Epigenetic modifications, particularly histone modifications, play a crucial role in ...

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 ...

Oncology and assistant professor of neurology, is one of 11 scholars who will be receiving a combined $6 million to fund the ...

MINNEAPOLIS, MN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- (NYSE American: FOXO) (the “Company” or “FOXO”), provides a shareholder letter from Mark White, Interim CEO of FOXO, on what has been achieved in ...

Theresa Ahrens holds a degree in molecular medicine and completed her doctorate on the subject of epigenetic cancer therapies ...

A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis ...